{
  "first_published_at": "2012-11-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON207188", 
  "title": "Reporting suspected adverse drug reactions to vaccines and biological medicines: please provide the brand name and batch number", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\", \"cardiovascular-disease-lipidology\", \"immunology-vaccination\", \"immunosuppression-transplantation\", \"neurology\", \"rheumatology\", \"dentistry\"], \"Audience:\": [\"Primary care\", \"Secondary care\", \"Dentists\"], \"Therapeutic area:\": [\"Cancer\", \"Cardiovascular disease and lipidology\", \"Immunology and vaccination\", \"Immunosuppression and transplantation\", \"Neurology\", \"Rheumatology\"]}", 
  "_document_number": 91, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/Yellowcard_icon.png", 
  "therapeutic_area": [
    "cancer", 
    "cardiovascular-disease-lipidology", 
    "immunology-vaccination", 
    "immunosuppression-transplantation", 
    "neurology", 
    "rheumatology", 
    "dentistry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Reporting suspected adverse drug reactions to vaccines and biological medicines: please provide the brand name and batch number</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--When reporting adverse drug reactions associated with biological medicines, such as biosimilar products or vaccines, it is important to provide the brand name and batch number. Products (biosimilar and reference) that have the same international non-proprietary name (INN) are not to be presumed identical, and there may be several different brands of a biological medicine for one particular condition (eg, different brands of influenza vaccines); furthermore, any concerns may be batch-specific.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<br />\nBiological medicines are medicines derived or manufactured from a &#8216;living&#8217; biological system. They encompass a broad range of therapeutic areas, including blood products, vaccines, antibodies and advanced therapies (such as gene and tissue therapy).<br />\n<br />\nBiological medicines and vaccines are fundamentally different from standard chemical medicines in terms of their complexity. Unlike most small molecule drugs, their characteristics are determined as much by the specific manufacturing process as the active ingredient itself.<br />\n<br />\nA wide variety of vaccines and biological medicines are available, and for many products a range of manufacturers produce the same &#8216;active ingredient&#8217;. These include a range of <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084739\" target=\"_blank\">&#8216;biosimilar&#8217; medicines</a>, several vaccines which protect against a given infection, and products such as human immunoglobulin.<br />\n<br />\nUnlike most standard generic medicines, the characteristics of such products will not be identical. For this reason, it is very important that safety surveillance is carried out on a brand/product-specific basis. In addition, these products may vary from batch-to-batch and so it is important that we receive information on batch number.<br />\n<br />\nAs a specific example, there are more than ten different brands of influenza vaccines available in the UK each year. However, it is very often the case that suspected ADR reports refer only to &#8216;influenza vaccine&#8217;. Following the guidance below will allow us to accurately evaluate the safety profile of specific products.<br />\n<br />\n<strong>Reporting suspected adverse drug reactions (ADRs)</strong><br />\nTo allow us to perform product/brand-specific pharmacovigilance, when reporting a suspected ADR to a biological medicine (such as blood products, antibodies and advanced therapies [such as gene and tissue therapy]) or vaccine, in addition to the substance please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number, on the report.<br />\n<br />\nAdditionally, when providing patients with details of the vaccine or biological medicine administered, it is good practice to give them details of the brand and batch number. This will allow patients and carers to more accurately report suspected ADRs to us.<br />\n<br />\nPlease report suspected ADRS to any medicine or vaccine to the <a href=\"http://yellowcard.mhra.gov.uk/\" target=\"_blank\">YellowCard Scheme</a><br />\n<br />\n<strong>Further information:</strong><br />\nBNF section: <a href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP60-general-guidance.htm\" target=\"_blank\">General guidance</a><br />\n<a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084739\" target=\"_blank\">Drug Safety Update article on biosimilar products</a><br />\nEuropean Medicines Agency: <a href=\"http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf\" target=\"_blank\">Questions and answers on biosimilar medicines</a><br />\n<br />\n<em>Article citation: Drug Safety Update November 2012, vol 6, issue 4: H1</em>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<br>\nBiological medicines are medicines derived or manufactured from a &#8216;living&#8217; biological system. They encompass a broad range of therapeutic areas, including blood products, vaccines, antibodies and advanced therapies (such as gene and tissue therapy).<br>\n<br>\nBiological medicines and vaccines are fundamentally different from standard chemical medicines in terms of their complexity. Unlike most small molecule drugs, their characteristics are determined as much by the specific manufacturing process as the active ingredient itself.<br>\n<br>\nA wide variety of vaccines and biological medicines are available, and for many products a range of manufacturers produce the same &#8216;active ingredient&#8217;. These include a range of <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084739\" target=\"_blank\">&#8216;biosimilar&#8217; medicines</a>, several vaccines which protect against a given infection, and products such as human immunoglobulin.<br>\n<br>\nUnlike most standard generic medicines, the characteristics of such products will not be identical. For this reason, it is very important that safety surveillance is carried out on a brand/product-specific basis. In addition, these products may vary from batch-to-batch and so it is important that we receive information on batch number.<br>\n<br>\nAs a specific example, there are more than ten different brands of influenza vaccines available in the UK each year. However, it is very often the case that suspected ADR reports refer only to &#8216;influenza vaccine&#8217;. Following the guidance below will allow us to accurately evaluate the safety profile of specific products.<br>\n<br>\n<strong>Reporting suspected adverse drug reactions (ADRs)</strong><br>\nTo allow us to perform product/brand-specific pharmacovigilance, when reporting a suspected ADR to a biological medicine (such as blood products, antibodies and advanced therapies [such as gene and tissue therapy]) or vaccine, in addition to the substance please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number, on the report.<br>\n<br>\nAdditionally, when providing patients with details of the vaccine or biological medicine administered, it is good practice to give them details of the brand and batch number. This will allow patients and carers to more accurately report suspected ADRs to us.<br>\n<br>\nPlease report suspected ADRS to any medicine or vaccine to the <a href=\"http://yellowcard.mhra.gov.uk/\" target=\"_blank\">YellowCard Scheme</a><br>\n<br>\n<strong>Further information:</strong><br>\nBNF section: <a href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP60-general-guidance.htm\" target=\"_blank\">General guidance</a><br>\n<a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084739\" target=\"_blank\">Drug Safety Update article on biosimilar products</a><br>\nEuropean Medicines Agency: <a href=\"http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf\" target=\"_blank\">Questions and answers on biosimilar medicines</a><br>\n<br>\n<em>Article citation: Drug Safety Update November 2012, vol 6, issue 4: H1</em>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-11-01", 
  "date_last_modified": "2013-01-28", 
  "_assets": [], 
  "_item_id": 91, 
  "summary": "", 
  "body": "Article date: November 2012   \nBiological medicines are medicines derived or manufactured from a ‘living’ biological system. They encompass a broad range of therapeutic areas, including blood products, vaccines, antibodies and advanced therapies (such as gene and tissue therapy).  \n  \nBiological medicines and vaccines are fundamentally different from standard chemical medicines in terms of their complexity. Unlike most small molecule drugs, their characteristics are determined as much by the specific manufacturing process as the active ingredient itself.  \n  \nA wide variety of vaccines and biological medicines are available, and for many products a range of manufacturers produce the same ‘active ingredient’. These include a range of ‘[biosimilar’ medicines](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084739), several vaccines which protect against a given infection, and products such as human immunoglobulin.  \n  \nUnlike most standard generic medicines, the characteristics of such products will not be identical. For this reason, it is very important that safety surveillance is carried out on a brand/product-specific basis. In addition, these products may vary from batch-to-batch and so it is important that we receive information on batch number.  \n  \nAs a specific example, there are more than ten different brands of influenza vaccines available in the UK each year. However, it is very often the case that suspected ADR reports refer only to ‘influenza vaccine’. Following the guidance below will allow us to accurately evaluate the safety profile of specific products.  \n  \nReporting suspected adverse drug reactions (ADRs)  \nTo allow us to perform product/brand-specific pharmacovigilance, when reporting a suspected ADR to a biological medicine (such as blood products, antibodies and advanced therapies [such as gene and tissue therapy]) or vaccine, in addition to the substance please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number, on the report.  \n  \nAdditionally, when providing patients with details of the vaccine or biological medicine administered, it is good practice to give them details of the brand and batch number. This will allow patients and carers to more accurately report suspected ADRs to us.  \n  \nPlease report suspected ADRS to any medicine or vaccine to the [YellowCard Scheme](http://yellowcard.mhra.gov.uk/)  \n  \nFurther information:  \nBNF section: [General guidance](http://www.medicinescomplete.com/mc/bnf/current/PHP60-general-guidance.htm)  \n[Drug Safety Update article on biosimilar products](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084739)  \nEuropean Medicines Agency: [Questions and answers on biosimilar medicines](http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf)  \n  \nArticle citation: Drug Safety Update November 2012, vol 6, issue 4: H1\n"
}